DMVO / Eng / Newsletter

Newsletter

Read the latest newsletter from DMVO

05.11.21
In this newsletter, Ricardo Valente, General Manager of MVO Portugal will share insights on the activity in Portugal.“The European Medicines Verification System (EMVS) is a world-first for its stakeholder model, its scale, its use of new technologies and represents an unprecedented step towards preventing falsified medicines from entering the legal supply chain. The EMVS provides an additional safety layer to more than 460 million people across the European Economic Area and Northern Ireland.

07.10.21
In this newsletter: Inese Erdmane, Chairwoman of the Board at LZVO, the Latvian Medicine Verification Organisation, will share insights with FMD."Latvia is a relatively small country, which is sometimes a disadvantage, but sometimes a great advantage. In the case of the implementation of the Falsified Medicines Directive (FMD), the small Latvian market was a privilege, as we were able to introduce a medicines verification system without a transition period. This means that on February 9, 2019, the medicines verification system in Latvia became fully operational to provide safe medicines to 2 million Latvian inhabitants.

09.09.21
In this newsletter: Pavlína Štisová from the Czech medicin verification organisation, CZMVO, will share insights with FMD. "The national organisation for medicin verification (NOOL) is responsible for implementing FMD and for operational reliability of the system NSOL.

08.07.21
In this newsletter: Arthur Isseyegh, director of CyMVO will share insights into FMD experiences from Cyprus. "Implementation of the FMD’s DR in Cyprus was particularly challenging mainly due to the fact that, the market size of pharmaceuticals is very small and extremely sensitive to additional administrative and/or procedural burdens.Financing the CyMVO was the primary issue that had to be delt with. Careful calculations were made, when setting onboarding and annual fees, so that, from a MAH’s perspective, the market would retain its financial attractiveness ensuring the availability of products in the market.

02.06.21

06.05.21
In this newsletter: Maria Ángeles Figuerola Santos, Director of SEVeM; the Spanish NMVO, will share insights into Spanish experiences with FMD."From the moment SEVeM took its first steps into the implementation of the FMD project, it was clear that achieving collaboration between all the stakeholders of the medicinal products supply chain in Spain was essential for its success, as well as collaboration at an European level with colleagues from other NMVOs and EMVO".

26.03.21

26.02.21

01.02.21

04.01.21

09.11.20

12.10.20
Alert Handling in another EU country, FMD experiences from IrelandIn this newsletter: Leonie Clarke, General Manager, IMVO, will share the Irish experiences gained up until now.

01.09.20
In week 33, 237 products with a “2”-tag was added to the medicinal price file.  A “2”- tag in the file implies that there are no more packs of that specific product on the market, released prior to the Falsified medicines Directive by 9th of February 2019. Therefore, triggered alerts must be investigated, and the packs put in quarantine during the investigation until the investigation has been finalized.

25.06.20
DMVO is experiencing alerts caused by products released prior to FMD. As DMVO is monitoring incoming alerts daily, alerts are handled but DMVO would appreciate if active batches released prior to FMD would be uploaded retrospectively.

29.05.20
In week 20, 63 products with a “2”-tag was added to the medicinal price file.A “2”- tag in the file implies that there are no more packs of that specific product on the market, released prior to the Falsified medicines Directive by 9th of February 2019. Therefore, triggered alerts must be investigated, and the packs put in quarantine during the investigation until the investigation has been finalized.

28.04.20
DMVO has derived much value from the comments given in the customer survey. It clarifies and provides DMVO insights into what is needed, wanted and how DMVO can become better at assisting

27.03.20
DMVO continues to investigate and lowering the number of alerts.  DMVO would like to take the opportunity to underline the importance of continuing the verification of prescriptive medicines during the COVID-19 pandemic. The European Commission expresses concerns due to the increasing online supply of false medicines for treatment of COVID-19. Through continued verification prior to delivery of a drug to the patient, it is ensured that the counterfeit drugs are kept out of the legal supply chain.

28.02.20
DMVO will focus on lowering alerts throughout 2020, in order to minimize resources for the entire supply chain investigating alerts triggered by technical or procedural errors.

28.01.20
Caps Lock causes scanner issues. In order to minimize unintended “serial numbers not found” – or ”pack not found” alerts due to scanner configuration issues, it has come to our attention that turning of Caps Lock on the key board has a positive effect and can lower false alerts.

11.12.19
One tim set off- and annual fee DMVO 2020.

06.11.19
Upgrade of Danish Medicine Verification System (DMVS)

27.09.19
OBPs are receiving alert messages in a new format.

30.08.19
Experiences after FMD Directive came into force.

08.07.19
The Pharmacies have started testing interfaces on their new robots.

06.06.19
First falsified packs identified by the EU FMD system.

01.05.19
The Danish Medicines Verification System has now been in use for more than 2.5 months.

​26.02.19
In continuation of the directive on Falsifield Medicines (2011/62/EU) per February 9, 2019, DMVO would like to share insight on how it has gone in Denmark.